Clinical Trials Browser

INDUSTRY × lenvatinib × Dermatologic × Clear all

NCT04305054 2026-05-28

KEYMAKER-U02

Phase 1/2 Completed

Diabetes Mellitus, Insulin-Dependent, 12, Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT03820986 2026-02-09

LEAP-003

Phase 3 Completed

674 enrolled 21 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT04889118 2025-12-23

LEAP-003

Phase 3 Completed

131 enrolled 16 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT04700072 2025-10-28

KEYMAKER-U02

Phase 1/2 Completed

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT05091346 2025-10-24

A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors

Phase 1/2 Completed

89 enrolled 24 charts

DermatologicGastrointestinal

Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis, Colorectal Neoplasms

NCT04305041 2025-08-29

KEYMAKER-U02

Phase 1/2 Completed

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT05620134 2024-10-15

Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer

Phase 1/2 Active not recruiting

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis, Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT01136967 2019-11-13

An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Phase 2 Completed

182 enrolled 63 charts

Melanoma

NCT01133977 2016-10-10

E7080 (Lenvatinib) in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma

Phase 1/2 Completed

97 enrolled 8 charts

Melanoma

NCT00121680 2015-12-11

A Phase I/Ib, Multicenter, Open-Label, Dose Escalation Study of E7080 in Patients With Solid Tumors and in Combination With Temozolomide in Patients With Advanced and/or Metastatic Melanoma

Phase 1 Completed

Melanoma, Neoplasms